Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
This study aims to provide a comprehensive understanding of sotorasib's mechanisms of action and resistance in NSCLC patients.
Trial Details
- NCT ID
- NCT05631249
- Phase
- PHASE2
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Status
- RECRUITING
- Cancer Type
- Small Cell (SCLC) Lung Cancer
- Interventions
- Locations (sample)
- Lyon, France|45.74906,4.84789
- Marseille, France|43.29695,5.38107
- Paris, France|48.85341,2.3488
- Paris, France|48.85341,2.3488
- Villejuif, France|48.7939,2.35992
Key Eligibility Criteria
- Age higher than 18 years;
- ECOG less or equal to 1 at the time of screening;
- Pathologically documented, previously treated, locally-advanced and unresectable or metastatic NSCLC with KRAS p.G12C mutation confirmed through mo…
- Subjects will have progressed or experienced disease recurrence on or after receiving at least 1 prior systemic therapy for locally advanced and un…
For full eligibility, visit ClinicalTrials.gov.